

# WHEN THAT LID LESION MAKES YOU SAY..HMMM

MARC R BLOOMENSTEIN, OD, FAAO  
SCOTTSDALE, ARIZON

1


## FINANCIAL DISCLOSURES FOR MARC R BLOOMENSTEIN, OD, FAAO

Allergan-Speaker/Consultant	• LENZ-Consultant	• STAAR Surgical-Speaker/Consultant
Avellino-Consultant	• Ocuphire-Consultant	• Sun-Speaker/Consultant
Bzura-Consultant	• OcuSOFT-Consultant	• Tarsus-Speaker/Consultant
Bausch & Lomb-Speaker/Consultant	• Olleyes-Consultant	• Thea-Consultant
Bruder-Consultant	• Oyster Point-Speaker/Consultant	• Topcon-Consultant
Dompe-Speaker/Consultant	• Novartis-Speaker/Consultant	
Eyevance-Consultant	• Reichert-Consultant	
Harrow-Speaker	• Sydnexus-Consultant	
Ivener-Consultant	• Sight Science-Speaker/Consultant	
	• Visus-Consultant	

All financial relationships have been mitigated.

2

## MANSCAPING 2.0



3

## MANSCAPING 2.0

- 77 YO HM
- "MY PRIMARY DOCTOR HAS BEEN ON MY ASS TO GET AN EXAM. SO, HERE I AM!"
- SMOKES AND "DON'T TELL ME I CAN'T DRINK MY BEERS"
- NIDM
  - Metformin 8.5ml/day
- NKMA
- OHX-NEGATIVE

4

## MANSCAPING 2.0


- Vasc
  - 20/40 ph 20/20
  - 20/25
- IOP
  - 13 mmHg OU
- Slex
  - OD: Grade2 demodex, MGGS 3, PCIOL (open capsule)
  - OS: Grade 3 demodex, MGGS 2, PCIOL (open capsule)
- Dilated Fundus Exam
  - C/D 0.35/0.40
  - Peripheral retina flat, NNOH/NNE, No Tears or holes.



5

## MANSCAPING 2.0

But my friend a  
on his brows. H  
was not funny. I  
I did ask him w  
looked again.



commented  
d, I said that  
and then I

6

## BE WARY OF

7

### Eyelid Neoplasms

- May arise from epidermis, dermis or eyelid adnexal structures
  - Keratinizing epidermis
  - Prominence of sebaceous glands and blood vessels
- Epidermal origin most common
- Main goal: identify and diagnose malignancy

8

Most periocular epithelial lesions non-malignant

Clinical judgment < 100% accurate

Whenever in doubt -> BIOPSY:

- absolutely necessary for the definitive Dx

### BENIGN OR MALIGNANT?

9


### CLINICAL EVALUATION: HISTORY

- Hx prior cancer
- Sun exposure
- Past radiation
- Smoking
- Skin type

10

### Clinical Signs

- Slow painless growth
- Ulceration, bleeding, crusting
- Irregular pigmentary changes
- Destruction of normal architecture
  - Lash loss, meibomian orifices
- Pearly edge, central ulceration
- Telangiectasia
- Loss of cutaneous wrinkles



11

### OTHER CLINICAL SIGNS

Palpable induration: infiltration into dermis, subcutaneous tissue

Lesions near punctum: possible lacrimal invasion

Fixation to deeper tissues/bone

Lymph nodes

Restricted EOM, proptosis: orbital invasion

12

## Basal Cell Carcinoma

- 90-95% of eyelid malignancies
- Most common malignant tumor of the eyes
- Arise from hair-bearing skin
- Cystic type resemble a benign inclusion cyst
  - Fibrosing difficult to Dx
    - Lie beneath and lose lashes
    - Entropion/ectropion
    - Lid notch/retraction/chalazia
    - Chronic blepharitis

13

## BASAL CELL CARCINOMA (BCC)

### Location

- LL: 50-60%
- MC: 25-30%
- UL: 15%
- LC: 5%

Hx: fair skin, sun exposure, smoking, prior BCC



Forms: nodular, morpheaform

### Rarely metastasize

- Recurrent or neglected may invade orbit and need exenteration

14

## BASAL CELL CARCINOMA (BCC)



15

## ULCERATED LID MARGIN LESION



16

## FINAL & DEFINITIVE DIAGNOSIS

### BIOPSY

- Incisional – when we suspect a malignant lesion
  - Shave Bx
  - Punch Bx
- Excisional – ideal when we suspect a benign lesion
  - Margins are not checked




17


## AFTER EXCISION



18



19




20



21




22



23



24

**BCC***Before**After*


25

**BCC***Before**After*

26

**BCC***Before**After*

27

**BCC***Before**After*


28

## OTHER CARCINOMAS

29

## SQUAMOUS CELL CARCINOMA

- 40x less common than BCC for the lid
- More common epithelial malignancy of the conjunctiva
- More aggressive
- Solar injury
- In areas of actinic keratosis,



Actinic Keratosis

30

## SQUAMOUS CELL CARCINOMA

- Potentiated by immunodeficiency
- May resemble various benign inflammatory lesions
  - Pseudoepitheliomatous hyperplasia
  - Inverted follicular keratosis
  - Keratocanthoma
- Metastasis by lymphatic, blood, direct extension (along nerves)


31

## SQUAMOUS CELL CARCINOMA



32

## SQUAMOUS CELL CARCINOMA



33

## SQUAMOUS CELL CARCINOMA



34

## SQUAMOUS CELL CARCINOMA



35

## SQUAMOUS CELL CARCINOMA



36



## TREATMENT OF SCC

- Aggressive surgical excision
- Recurrences may require orbital exenteration

37

## SEBACEOUS ADENOCARCINOMA

- Rare malignancy
  - 1-5.5% of eyelid malignancies in U.S.
  - 33% of eyelid malignancies in China
- Highly malignant, lethal
- Sebaceous gland origin: meibomian, Zeis, caruncle, eyebrow or facial skin


38

## SEBACEOUS ADENOCARCINOMA

- F>M
- UL>LL
- Multicentric origin common

39

## SEBACEOUS ADENOCARCINOMA



40

## SEBACEOUS ADENOCARCINOMA



41

## PRESENTATION

- Patients commonly > 50 y/o
- Yellowish coloration
- Often masquerades as chalazion, chronic blepharitis, SLK, pannus associated w/ adult inclusion conjunctivitis
  - Misdiagnosis is delayed by average of 3 yrs.

42

## KEY POINT

- Beware of the “chalazion” that later causes loss of eyelashes and destruction of meibomian gland orifices

43

## MALIGNANT MELANOMA


- 5% of all skin cancers
- <1% of eyelid malignancies
- UV, genetic predisposition, mutagens
- Arise de novo, from nevi or lentigo maligna
- Acquired pigmented lesion >20-30y/o

44

## MALIGNANT MELANOMA

- Appearance: variable pigmentation, irregular borders, may ulcerate and bleed
- Forms
  - Lentigo maligna melanoma\*
  - Nodular melanoma\*
  - Superficial spreading melanoma
  - Arco-lentiginous melanoma

45



## MELANOMA

46

## TREATMENT OF MM

- Depth of invasion affects prognosis
- Preop metastatic workup
- Regional lymph node dissection

47



## MM REFERRAL

48



**2 DAYS  
PO**



49

**6M PO**



50

## MELANOMA

*Before*



*After*



51

## CONCLUSION

- Most eyelid lesions epidermal origin
- Early detection of eyelid malignancy important
- Clinical examination important, but not 100% accurate
- Biopsy if not sure



52

“When in doubt  
cut it out!”



53

**THANK YOU..**

MBLOOEMNSTEIN@GMAIL.COM

54